Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nuria Riesco

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
The Journal of Headache and Pain|November 22, 2023
Long-term effectiveness and tolerability of galcanezumab in patients with migraine excluded from clinical trials: real world evidence of 1055 patients with 1 year follow-up from the Galca-Only registryVictor Obach, Fernando Velasco, Rocio Alvarez Escudero, et al.
Neurology|January 28, 2026
Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine: 2-Year Results From the EUREkA CohortEdoardo Caronna, Rut Mas-de-Les-Valls, Gabriella Egeo, et al.
Neurology|May 27, 2026
Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine: 2-Year Results From the EUREkA CohortEdoardo Caronna, Rut Mas-de-Les-Valls, Gabriella Egeo, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
The Journal of Headache and Pain|November 22, 2023
Long-term effectiveness and tolerability of galcanezumab in patients with migraine excluded from clinical trials: real world evidence of 1055 patients with 1 year follow-up from the Galca-Only registryVictor Obach, Fernando Velasco, Rocio Alvarez Escudero, et al.
Neurology|January 28, 2026
Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine: 2-Year Results From the EUREkA CohortEdoardo Caronna, Rut Mas-de-Les-Valls, Gabriella Egeo, et al.
Neurology|May 27, 2026
Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine: 2-Year Results From the EUREkA CohortEdoardo Caronna, Rut Mas-de-Les-Valls, Gabriella Egeo, et al.
Pageof 2